Utilisation of the ESMO-MCBS in practice of HTA

作者：Wild C^*; Groessmann N; Bonanno P V; Bucsics A; Furst J; Garuoliene K; Godman B; Gulbinovic J; Jones J; Pomorski M K; Emprechtinger R

来源：Annals of Oncology, 2016, 27(11): 2134-2136.

DOI：10.1093/annonc/mdw297

For utilising the ESMO-MCBS in pre-reimbursement HTA an adapted version is proposed: prioritized use of the patient-relevant endpoint OS and QoL; use of point estimates; transparent reporting of adverse events incl. therapy discontinuation. In applying this adapted version the deviation is on average 1-2 scores lower than the ESMO scoring.